Cargando…

Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis

BACKGROUND: This meta-analysis was conducted to investigate the effects of incretin-based therapeutic agents, including the latest agent tirzepatide, on renal outcomes in patients with type 2 diabetes. METHODS: MEDLINE (via PubMed) and Cochrane databases were searched for studies involving incretin-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mima, Akira, Gotoda, Hidemasa, Lee, Rina, Murakami, Ami, Akai, Ryosuke, Lee, Shinji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009293/ https://www.ncbi.nlm.nih.gov/pubmed/36923991 http://dx.doi.org/10.1016/j.metop.2023.100236

Ejemplares similares

Case Report: IgG4-related kidney disease complicated by interstitial pneumonia
por: Mima, Akira, et al.
Publicado: (2023)

Effect of finerenone on diabetic kidney disease outcomes with estimated glomerular filtration rate below 25 mL/min/1.73 m(2)
por: Mima, Akira, et al.
Publicado: (2023)

Structural determinants of dual incretin receptor agonism by tirzepatide
por: Sun, Bingfa, et al.
Publicado: (2022)

The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
por: El, Kimberley, et al.
Publicado: (2023)

The catcher in the gut: Tirzepatide, a dual incretin analog for the treatment of type 2 diabetes mellitus and obesity
por: Lempesis, Ioannis G., et al.
Publicado: (2022)

Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
por: Mima, Akira
Publicado: (2016)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
por: Liarakos, Alexandros Leonidas, et al.
Publicado: (2023)

Tirzepatide: A Systematic Update
por: Forzano, Imma, et al.
Publicado: (2022)

Adverse Events Related to Tirzepatide
por: Mishra, Rahul, et al.
Publicado: (2023)

Tirzepatide for type 2 diabetes
por: Anderson, Sarah L, et al.
Publicado: (2023)

Advent of tirzepatide: boon for diabetic and obese?
por: Bhusal, Amrit
Publicado: (2023)

Tirzepatide and prevention of chronic kidney disease
por: Bosch, Catalina, et al.
Publicado: (2022)

Tirzepatide-Induced Injection Site Reaction
por: Mizumoto, Junki
Publicado: (2023)

Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
por: Karrar, Hani Raka, et al.
Publicado: (2023)

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide
por: Urva, Shweta, et al.
Publicado: (2021)

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
por: Sattar, Naveed, et al.
Publicado: (2022)

Tirzepatide—Friend or Foe in Diabetic Cancer Patients?
por: Samuel, Samson Mathews, et al.
Publicado: (2022)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
por: Wang, Lijing
Publicado: (2022)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
por: Anala, Alekya Devi, et al.
Publicado: (2023)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

Understanding the Cardiovascular Effects of Incretin
por: Yoon, Ji Sung, et al.
Publicado: (2011)

Incretin Concepts
por: Bloomgarden, Zachary T.
Publicado: (2010)

Inflammation and incretins
por: Hatwal, Amitabh
Publicado: (2012)

Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
por: Tang, Yan, et al.
Publicado: (2022)

Weight loss efficiency and safety of tirzepatide: A Systematic review
por: Lin, Fei, et al.
Publicado: (2023)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
por: Sinha, Rachel, et al.
Publicado: (2023)

Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
por: De Block, Christophe, et al.
Publicado: (2022)

Tirzepatide: A Promising Drug for Type 2 Diabetes and Beyond
por: Dutta, Palak, et al.
Publicado: (2023)

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1–4 Trials
por: Rosenstock, Julio, et al.
Publicado: (2023)

Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
por: Yu, Yunfeng, et al.
Publicado: (2022)

Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis
por: Guan, Ruifang, et al.
Publicado: (2022)

Incretin secretion stimulated by ursodeoxycholic acid in healthy subjects
por: Murakami, Masanori, et al.
Publicado: (2013)

IgA nephropathy after COVID-19 vaccination and analysis of reported cases
por: Mima, Akira, et al.
Publicado: (2023)

Pancreatitis Associated With Incretin-Based Therapies
por: Iyer, Shridhar N., et al.
Publicado: (2013)

GIP: An Inconsequential Incretin or Not?
por: Pratley, Richard E.
Publicado: (2010)

Pleiotropic effects of incretins
por: Gupta, Vishal
Publicado: (2012)

Incretin-based therapies
por: Stonehouse, Anthony H, et al.
Publicado: (2012)

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
por: Willard, Francis S., et al.
Publicado: (2020)

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program
por: le Roux, Carel W., et al.
Publicado: (2022)

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
por: Rohani, Pejman, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8h7ahc3h20ashhq4gandvm2s0r